Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Athira Pharma Inc (ATHA)

Athira Pharma Inc (ATHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,621
  • Shares Outstanding, K 3,944
  • Annual Sales, $ 0 K
  • Annual Income, $ -96,940 K
  • EBIT $ -39 M
  • EBITDA $ -39 M
  • 60-Month Beta 2.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.99
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -9.68
  • Most Recent Earnings $-1.68 on 11/06/25
  • Next Earnings Date 02/26/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -3.90
  • Growth Rate Est. (year over year) +25,715.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.80 +77.63%
on 12/16/25
8.36 -19.26%
on 12/18/25
+2.74 (+68.33%)
since 12/09/25
3-Month
3.60 +87.50%
on 10/16/25
8.36 -19.26%
on 12/18/25
+2.83 (+72.19%)
since 10/09/25
52-Week
2.20 +207.52%
on 04/08/25
8.36 -19.26%
on 12/18/25
+0.84 (+14.29%)
since 01/08/25

Most Recent Stories

More News
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”

BOTHELL, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with...

ATHA : 6.75 (-6.12%)
LONA : 6.58 (+0.61%)
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing...

ATHA : 6.75 (-6.12%)
Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update

Continuing to explore strategic alternatives focusing on maximizing stockholder value   Presented results from Phase 1 clinical trial of ATH-1105 in healthy volunteers demonstrating a favorable...

ATHA : 6.75 (-6.12%)
Athira Pharma Announces Reverse Stock Split

BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules...

ATHA : 6.75 (-6.12%)
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025

BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...

ATHA : 6.75 (-6.12%)
Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

BOTHELL, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...

ATHA : 6.75 (-6.12%)
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

ATHA : 6.75 (-6.12%)
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

ATHA : 6.75 (-6.12%)
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

ATHA : 6.75 (-6.12%)
Athira Pharma Presents Promising Preclinical Data on ATH-1105 for Neuroprotection in ALS at International Symposium

Athira Pharma presented preclinical data on ATH-1105's neuroprotective effects in ALS at an international symposium in Montreal.Quiver AI SummaryAthira Pharma, Inc., a clinical-stage biopharmaceutical...

ATHA : 6.75 (-6.12%)

Business Summary

Athira Pharma Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira Pharma Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 7.92
2nd Resistance Point 7.64
1st Resistance Point 7.19
Last Price 6.75
1st Support Level 6.46
2nd Support Level 6.18
3rd Support Level 5.73

See More

52-Week High 8.36
Last Price 6.75
Fibonacci 61.8% 6.00
Fibonacci 50% 5.28
Fibonacci 38.2% 4.55
52-Week Low 2.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar